Residual disease status during the first 6 months of treatment and relapse incidence
| MRD status . | d 15 . | d 33 . | wk 124-150 . | wk 22-244-150 . | |||||
|---|---|---|---|---|---|---|---|---|---|
| Relative (% NC) . | Absolute (cells/μL BM) . | Relative Rx/pts . | Absolute Rx/pts . | Relative Rx/pts . | Absolute Rx/pts . | Relative Rx/pts . | Absolute Rx/pts . | Relative Rx/pts . | Absolute Rx/pts . |
| ≥ 10% | > 1000 | 4/8 | 4/8 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-9.9% | 100-999 | 5/30 | 5/19 | 3/3 | 3/3 | 0 | 1/1 | 0 | 0 |
| 0.1-0.99% | 10-99 | 2/20 | 1/19 | 5/11 | 5/10 | 4/4 | 4/4 | 0 | 2/2 |
| 0.01-0.099% | 1-99 | 1/23 | 1/25 | 0/20 | 1/20 | 2/2 | 2/2 | 3/3 | 1/1 |
| < 0.01% | < 1 | 0/2 | 1/12 | 1/5 | 0/6 | 1/5 | 0/4 | 1/2 | 1/2 |
| Negative | 1/11 | 1/11 | 4/59 | 4/59 | 5/52 | 5/49 | 6/46 | 6/46 | |
| Total eligible | 13/94 | 13/94 | 13/98 | 13/98 | 12/63 | 12/60 | 10/51 | 10/51 | |
| (Total) | (101) | (101) | (105) | (105) | (68) | (64) | (54) | (53) | |
| MRD status . | d 15 . | d 33 . | wk 124-150 . | wk 22-244-150 . | |||||
|---|---|---|---|---|---|---|---|---|---|
| Relative (% NC) . | Absolute (cells/μL BM) . | Relative Rx/pts . | Absolute Rx/pts . | Relative Rx/pts . | Absolute Rx/pts . | Relative Rx/pts . | Absolute Rx/pts . | Relative Rx/pts . | Absolute Rx/pts . |
| ≥ 10% | > 1000 | 4/8 | 4/8 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-9.9% | 100-999 | 5/30 | 5/19 | 3/3 | 3/3 | 0 | 1/1 | 0 | 0 |
| 0.1-0.99% | 10-99 | 2/20 | 1/19 | 5/11 | 5/10 | 4/4 | 4/4 | 0 | 2/2 |
| 0.01-0.099% | 1-99 | 1/23 | 1/25 | 0/20 | 1/20 | 2/2 | 2/2 | 3/3 | 1/1 |
| < 0.01% | < 1 | 0/2 | 1/12 | 1/5 | 0/6 | 1/5 | 0/4 | 1/2 | 1/2 |
| Negative | 1/11 | 1/11 | 4/59 | 4/59 | 5/52 | 5/49 | 6/46 | 6/46 | |
| Total eligible | 13/94 | 13/94 | 13/98 | 13/98 | 12/63 | 12/60 | 10/51 | 10/51 | |
| (Total) | (101) | (101) | (105) | (105) | (68) | (64) | (54) | (53) | |
Rx indicates relapses; pts, patients (eligible, total patients excluding prematurely censored due to transplantation or early death).
Data from all available patients included (only the first half of patients was consecutively investigated at this time point, whereas samples from later patients were tested only if MRD+ at the preceding time point).